Skip to main content

Beyond SBIR – Additional Ways to Partner with NIH


May 14, 2019 10:00 amMay 14, 2019 11:30 am



, CA

Registration Closed

The National Institutes of Health (NIH) is the largest basic science research institute in the world and the largest provider of direct funding support in the world – over $30B this fiscal year. Part of this support includes the Small Business Innovation Research (SBIR) Program, which provides essential seed capital for early-stage companies. The NIH also possesses the largest number of hospital beds in the country, and patients treated at its Clinical Center receive unique care, at no cost.

The NIH’s technology transfer offices are also a resource for companies – one of the go-to places for the healthcare industry to work with a thought-leader, overcome a technology or knowledge gap, and get their products to market. The NIH engages with companies in ways that include:
  • Connecting them to translational and clinical innovators across 27 Institutes and centers that cover nearly every disease and disorder imaginable – and marketable.
  • Developing drugs – as well as devices, diagnostics, wearable and digital health solutions, and software.
  • Executing technology development and commercialization partnerships at the rate of more than one per week – current >200 in place.
  • Out-licensing the NIH’s cutting-edge innovations – with licensees ranging from start-ups to big pharma – at the rate of more than three per week.
  • Collaborating on technology development. Technologies that have either originated from the NIH or that have been co-developed with an industry partner have received three FDA approvals in just the last six months.

The NIH is also the largest provider of indirect/in-kind support in the world. Their indirect cost rate is extremely lowand these arrangements can sometimes be on a cost-sharing basis. .
  • They provide research tools – mice, cell lines, antibodies – at minimal cost.
  • They work with companies to run hundreds of first-in-human and clinical validation studies.
  • There are hundreds of assets available for licensing for which they take no equity.
  • Their royalty rates are highly competitive. As a result, in total, NIH executes more than 4000 agreements each year.

NIH is focused on accelerating and promoting economic development. That means working with companies to positively impact chances as an equity investment, a M&A target and/or, an active employer.
Assets available for licensing/collaborations include:
  • Small molecules
  • Biologics
  • Devices
  • Diagnostics
  • Vaccines
  • Wearables and Digital health
  • Software
  • Research tools (cells, mice, etc.)
    • Non-patented technologies available under non-exclusive licenses
The NIH is a resource that companies should consider to bolster their pipeline or solve a development problem. Join the webinar with Biocom on May 14, 2019 at 10:00AM to learn more about how your organization can partner with the NIH.

Price of Admission


Today’s Price: 0

Important Dates


Registration before

Registration before

Registration before

Registration cost


Refund before 2019-05-13


Refund before

Refund Before

Registration Closed